Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients

Ann Hematol. 2021 Apr;100(4):1111-1113. doi: 10.1007/s00277-020-04333-7. Epub 2020 Nov 11.

Authors

P Zappasodi¹, M Brociner², G Merati², M E Nizzoli², E Roncoroni³, E Boveri⁴, C Castagnola³, L Arcaini^{3

2}

Affiliations

¹ Division of Hematology, Fondazione IRCCS Policlinico San Matteo, V.le Golgi, 19, 27100, Pavia, Italy. p.zappasodi@smatteo.pv.it.
² Department of Molecular Medicine, University of Pavia, Pavia, Italy.
³ Division of Hematology, Fondazione IRCCS Policlinico San Matteo, V.le Golgi, 19, 27100, Pavia, Italy.
⁴ Unit of Anatomic Pathology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

PMID: 33175198
DOI: 10.1007/s00277-020-04333-7

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / toxicity
Azacitidine / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / pathology
Male
Middle Aged
Sulfonamides / therapeutic use*

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
Azacitidine
venetoclax